Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 4Lymphoma, Mantle-Cell 4Colorectal Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Waldenstrom Macroglobulinemia 2Squamous Cell Carcinoma of Head and Neck 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Acute 2Leukemia 2Hodgkin Disease 2Gliosarcoma 2Glioma 2Congenital Abnormalities 2Colonic Neoplasms 2Burkitt Lymphoma 2

Interventions

Temozolomide 64Radiotherapy 53Filgrastim 28Carboplatin 24Etoposide 20Irinotecan 17Vincristine 16Cyclophosphamide 16Cisplatin 15Carmustine 14Peripheral Blood Stem Cell Transplantation 13Magnetic Resonance Spectroscopy 12Bevacizumab 12Thiotepa 11Thalidomide 11Chemotherapy, Adjuvant 11Methotrexate 10Paclitaxel 9Granulocyte Colony-Stimulating Factor 9etoposide phosphate 8Surgical Procedures, Operative 8Procarbazine 8Ifosfamide 8sargramostim 7Topotecan 7O(6)-benzylguanine 7Lomustine 7Busulfan 7Radiation 6Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Central Nervous System Neoplasms × Pharmacogenomic Testing × Clear all
NCT00770471 2018-06-27

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
24 enrolled
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡